<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01113112</url>
  </required_header>
  <id_info>
    <org_study_id>200308061</org_study_id>
    <secondary_id>R01CA104825</secondary_id>
    <nct_id>NCT01113112</nct_id>
  </id_info>
  <brief_title>Biobehavioral-Cytokine Interactions in Ovarian Cancer</brief_title>
  <acronym>VEGF</acronym>
  <official_title>Biobehavioral-Cytokine Interactions in Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan Lutgendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand relationships between behavioral factors,&#xD;
      hormones, and chemicals produced by the body that may help tumor growth in ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian cancer is the second most common gynecologic cancer. Because of low rates of survival&#xD;
      for the majority of ovarian cancer patients, identification of factors contributing to tumor&#xD;
      progression is of paramount importance. Epidemiologic studies have suggested an association&#xD;
      between biobehavioral factors such as life stress, depression, low social support and cancer&#xD;
      progression. Direct links have been demonstrated between biobehavioral factors and cytokines&#xD;
      supporting angiogenesis, the formation of new blood vessels that enhance tumor growth and&#xD;
      progression. However, little is known regarding tumor associated macrophages (TAM) and&#xD;
      interactions between TAM tumor cells in a way that favors tumor growth, but there is&#xD;
      preliminary data indicating that ovarian cancer patients with higher levels of depressive&#xD;
      symptoms and life stress have greater TAM production of matrix metalloproteinase-9, a key&#xD;
      molecule promoting angiogenesis and tumor invasion. We also have preliminary data that&#xD;
      ovarian cancer patients with high levels of depressive symptoms accompanied by low social&#xD;
      support have greater tumor expression of a number of genes related to inflammation and tumor&#xD;
      progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2003</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Actual">November 10, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biobehavioral Factors</measure>
    <time_frame>1 year post op</time_frame>
    <description>Pathways by which biobehavioral factors contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">613</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Biobehavioral factors</arm_group_label>
    <description>Those with biobehavioral factors that contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, saliva, tissue, ascites&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Gyn/Onc patients at the University of Iowa and Washington University School of Medicine&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a histologic diagnosis of epithelial ovarian cancer, primary peritoneal&#xD;
             carcinoma, or fallopian tube cancer; FIGO stage I to IV defined surgically at the&#xD;
             completion of the initial abdominal surgery and with appropriate tissue available for&#xD;
             histologic evaluation.&#xD;
&#xD;
          -  Patients with the following histologic epithelial cell types are eligible: serous&#xD;
             adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated&#xD;
             carcinoma, clear cell carcinoma, mixed epithelial carcinoma, or adenocarcinoma not&#xD;
             otherwise specified. However, the histologic features must be compatible with primary&#xD;
             Mullerian epithelial adenocarcinoma.&#xD;
&#xD;
          -  GOG performance status 0-3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of borderline epithelial ovarian tumor (formerly: tumors of&#xD;
             low malignant potential&quot; or recurrent invasive epithelial ovarian, primary peritoneal,&#xD;
             or fallopian tube cancer treated with chemotherapy or radiotherapy previously are&#xD;
             excluded.&#xD;
&#xD;
          -  Patients who received neoadjuvant chemotherapy for ovarian, primary peritoneal, or&#xD;
             fallopian tube carcinoma are excluded.&#xD;
&#xD;
          -  Non-epithelial ovarian cancers or metastases to the ovaries from organs are excluded.&#xD;
&#xD;
          -  Previous cancer diagnosis except for basal cell carcinoma of the skin or history of&#xD;
             lymphoma.&#xD;
&#xD;
          -  Pregnancy or age &lt;18 years old&#xD;
&#xD;
          -  Use of systemic glucocorticoids such as prednisone or decadron in the last 30 days&#xD;
&#xD;
          -  Comorbid conditions: Addison's disease, autoimmune hepatitis, hepatitis B, hepatitis&#xD;
             C, AIDS or HIV, lupus erythematosus, mixed connective tissue disease, rheumatoid&#xD;
             arthritis.&#xD;
&#xD;
          -  Inability to accurately answer questions (e.g. a condition such as dementia)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Lutgendorf, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Premal Thaker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2010</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Susan Lutgendorf</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Ovarian Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

